Table 1.
Baseline characteristics
| Patient | Age (y) | BRAF Status | Time Between Diagnosis Of Brain Mets And Bevacizumab (mo) | Past Treatment Of Brain Metastases | |||
|---|---|---|---|---|---|---|---|
| Surgical Resection | SRS | WBRT | Systemic Therapy | ||||
| P01 | 40 | V600E | 16.2 | 3 | 2 | No | BRAFi + MEKi |
| P02 | 46 | V600E | 3.1 | 0 | 0 | Yes | BRAFi + MEKi, ipilimumab |
| P03 | 70 | Wild type | 3.5 | 1 | 0 | Yes | Nil |
| P04 | 58 | V600E | 2.0 | 0 | 0 | Yes | BRAFi + MEKi, temozolomide |
| P05 | 63 | Wild type | 2.9 | 0 | 0 | Yes | Ipilimumab, temozolomide, pembrolizumab |
| P06 | 57 | K601E | 10.3 | 2 | 0 | Yes | BRAFi, ipilimumab |
| P07 | 58 | Wild type | 40.3 | 4 | 6 | Yes | Fotemustine, ipilimumab + 2 reinductions |
| P08 | 73 | Wild type | 1.6 | 0 | 0 | Yes | Pembrolizumab |
| P09 | 51 | V600E | 22.5 | 1 | 1 | Yes + retreat | BRAFi + MEKi, pembrolizumab |
| P10 | 76 | V600K | 11.3 | 0 | 0 | Yes | BRAFi + MEKi, ipilimumab, pembrolizumab |
| P11 | 33 | V600E | 30.1 | 3 | 0 | Yes + retreat | BRAFi + MEKi |
| P12 | 32 | V600E | 11.0 | 2 | 7 | Yes | BRAFi + MEKi, temozolomide, ipilimumab |
Abbreviations: BRAFi, BRAF inhibitor, including dabrafenib or vemurafenib; MEKi, MEK inhibitors, including trametinib or cobimetinib; SRS, stereotactic radiosurgery; WBRT, whole brain radiotherapy.